New drug approvals - December 2022
Product Name
|
LYPSTAPLUS FILM-COATED TABLET 20MG/10MG, 10MG/10MG
|
Active Ingredient
|
Rosuvastatin, ezetimibe
|
Application type
|
NDA-2: New combination
|
Product Registrant
|
ABBOTT LABORATORIES (SINGAPORE) PRIVATE LIMITED
|
Date of Approval
|
06/12/2022
|
Registration No.
|
SIN16650P, SIN16651P
|
Indications:
LYPSTAPLUS® is indicated as adjunct to diet for treatment of primary hypercholesterolemia as substitution therapy in adult patients adequately controlled with the individual substances given concurrently at the same dose level as in the fixed dose combination, but as separate products.
|
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Approvals